Lipocine (NASDAQ:LPCN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research note published on Sunday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Price Performance

Shares of Lipocine stock opened at $4.54 on Friday. Lipocine has a 1-year low of $3.20 and a 1-year high of $11.79. The business’s fifty day moving average price is $4.77 and its two-hundred day moving average price is $4.76. The company has a market capitalization of $24.29 million, a P/E ratio of -5.97 and a beta of 1.23.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter.

Institutional Trading of Lipocine

An institutional investor recently raised its position in Lipocine stock. Renaissance Technologies LLC boosted its position in Lipocine Inc. (NASDAQ:LPCN) by 21.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,697 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,600 shares during the period. Renaissance Technologies LLC owned approximately 0.48% of Lipocine worth $212,000 as of its most recent SEC filing. 9.11% of the stock is currently owned by institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.